• Nxera Pharma expects fiscal 2026 revenue of JPY 33.8 billion, with sales and costs tracking its original forecast.
• Full-year guidance projects core operating profit of JPY 7.8 billion; IFRS operating profit is forecast at JPY 700 million.
• Nine-month revenue rose 27% to JPY 27.74 billion, supported by product sales growth and partner milestone payments.
• Core operating profit reached JPY 9.82 billion in the nine months, exceeding the full-year forecast.
• Longer-term targets call for revenue above JPY 50 billion by 2030, with an operating margin exceeding 30%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nxera Pharma Co. Ltd. published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.